KEYTRUDA 2020 Worldwide Sales Grew 30% to $14.4 Billion
https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2020-financial-results/
For comparison:
KEYTRUDA 2019 Worldwide Sales Grew 55% to $11.1 Billion
https://www.businesswire.com/news/h...-Quarter-and-Full-Year-2019-Financial-Results
With Keytruda growth starting to taper off Merck will be very keen to look at RACE - particularly if Bisantrene can help improve efficacy of Keytruda. They will also be battling it out with BMS who have their own PD-1 drug OPDIVO.
I will update the below when I have more data (and the time to update it). We may see analysts release 2027 forecasts.
Also - just found this stat from 2018. Opdivo sells for about USD $150K in the US.
https://endpts.com/bristol-myers-wi...setting-precedent-for-checkpoint-wave-report/
Pillar 1 - FTO (new thread), page-48
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.63 |
Change
-0.065(3.85%) |
Mkt cap ! $277.7M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.66 | $1.57 | $267.7K | 164.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2500 | $1.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.63 | 626 | 1 |
View Market Depth
| Last trade - 14.38pm 04/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |